Connor, Clark & Lunn Investment Management (CC&L)
SRNE

Connor, Clark & Lunn Investment Management (CC&L)’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-26,495
Closed -$202K – 1246
2021
Q3 		$202K Buy
+26,495
New +$225K ﹤0.01% 947
2018
Q2 		– Sell
-118,685
Closed -$611K – 1120
2018
Q1 		$611K Buy
+118,685
New +$844K ﹤0.01% 542
2016
Q1 		– Sell
-16,900
Closed -$147K – 921
2015
Q4 		$147K Buy
+16,900
New +$143K ﹤0.01% 726

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s SRNE Position: Q4 2021 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2021, closing a stake of 26,495 shares — an estimated $202K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in SRNE in Q4 2015 and held it in 3 quarters. The position peaked at $611K in Q1 2018. 234 funds tracked by Wall St. Rank hold SRNE as of Q4 2021.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 26,495 Sorrento Therapeutics, Inc. shares in Q4 2021, an estimated $202K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Sorrento Therapeutics, Inc. in Q4 2015 and held it in 3 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Sorrento Therapeutics, Inc. position peaked at $611K in Q1 2018.
  • 234 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2021.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2021, filed 10 Feb 2022.